Collectively, these findings illustrate that triptolide modulates cell cycle progression primarily by inducing G0/G1 phase arrest through mechanisms such as enhancing cell cycle inhibitors and suppressing cyclins and CDKs, while also affecting S and G2/M phases, highlighting its potential as a multifaceted anti-cancer agent targeting diverse cell cycle regulatory pathways. Here, PCNA is linked to cancer.